亚太地区人类微生物组市场至 2025 年 - 按产品(益生菌、食品、益生元、医用食品、诊断设备、药物和补充剂)、疾病(肥胖、糖尿病、自身免疫性疾病、癌症、精神障碍等)进行区域分析和预测、应用(治疗和诊断)和国家

Historic Data: 2015-2016   |   Base Year: 2017   |   Forecast Period: 2018-2025


No. of Pages: 155    |    Report Code: TIPRE00003317    |    Category: Life Sciences

Asia Pacific Human Microbiome Market

亚太人类微生物组市场预计将从 2017 年的 41.73 美元增至 2025 年的 2.0781 亿美元。预计从 2018 年开始,该市场将以 22.8% 的复合年增长率增长 - 2025年。

生活方式的改变导致慢性病增加以及对人类微生物组治疗方法日益浓厚的兴趣等因素推动了市场的增长。然而,严格的监管环境和对人类微生物组科学认识的缺乏可能会对未来几年市场的增长产生负面影响。

益生菌、益生元膳食含有活微生物的补充剂和食品已经过彻底研究,以评估它们对人类健康的影响。 2018年肠道健康大会在亚洲香港举行,会议详细探讨了饮食与健康。个性化营养、胃肠微生物组以及有关临床研究、诊断研究、治疗方法、生物标志物开发、分子治疗和胃肠疾病的多个案例研究。此外,第五届微生物组研发与商业合作大会于2019年3月在亚洲台湾举行,会议重点关注肠道微生物组、皮肤微生物组、婴儿、女性和口腔健康、治疗学、微生物组和饮食的最新发展。

此外,许多公司正在设计和开发许多微生物疗法。因此,对人类微生物组疗法的日益关注是未来几年推动人类微生物组市场增长的主要因素。

预计日本将引领人类微生物组的采用整个亚太地区在预测期内。日本的研究人员正在利用对该国百岁老人的研究结果来尝试生产新产品,以复制其微生物群的有益方面。此次合作的目标是解决推进干细胞研究的一些主要技术障碍。此外,Cykinso(东京)获得了地区医疗保健产业支援基金的230万美元(2.7亿日元)资金,开发和销售Mykinso或肠道菌群检测试剂盒。该公司计划将这些资金用于业务发展目的,其中包括利用肠道菌群测试收集的数据开发一个提供营养指导的系统。因此,政府采取的投资和举措可能会推动预测期内市场的增长。

亚太地区其他地区到 2027 年人类微生物组市场收入和预测(十亿美元)



亚太地区人类微生物组 - 市场细分



按产品


•益生菌
•食品
•益生元
•药用食品
•诊断装置
•毒品
•补充剂


亚太地区人类微生物组-市场细分



按疾病分类


•肥胖
•糖尿病
•自身免疫性疾病
•癌症
•精神障碍
•其他

亚太地区人类微生物组-市场细分



按应用


•治疗学
•诊断

按国家/地区


•美国
•加拿大
•墨西哥

提及的公司


• Enterome
• MicroBiome Therapeutics, LLC
• Rebiotix Inc.
•养乐多本社株式会社
• Osel Inc.
•韦丹塔生物科学公司
•元生物组学公司
•合成生物制剂公司
•杜邦
• BiomX 有限公司

Asia Pacific Human Microbiome Strategic Insights

Strategic insights for Asia Pacific Human Microbiome involve closely monitoring industry trends, consumer behaviours, and competitor actions to identify opportunities for growth. By leveraging data analytics, businesses can anticipate market shifts and make informed decisions that align with evolving customer needs. Understanding these dynamics helps companies adjust their strategies proactively, enhance customer engagement, and strengthen their competitive edge. Building strong relationships with stakeholders and staying agile in response to changes ensures long-term success in any market.

strategic-framework/asia-pacific-human-microbiome-market-strategic-framework.webp
Get more information on this report

Asia Pacific Human Microbiome Report Scope

Report Attribute Details
Market size in 2017 US$ 41.73 Million
Market Size by 2025 US$ 207.81 Million
Global CAGR (2018 - 2025) 22.8%
Historical Data 2015-2016
Forecast period 2018-2025
Segments Covered By 产品
  • 益生菌
  • 食品
  • 益生元
  • 医疗食品
  • 诊断设备
  • 药物
  • 补充剂
By 疾病
  • 肥胖症
  • 糖尿病
  • 自身免疫性疾病
  • 癌症
  • 精神障碍
By 应用
  • 治疗学
  • 诊断学
Regions and Countries Covered 亚太地区
  • 中国
  • 印度
  • 日本
  • 澳大利亚
  • 亚太其他地区
Market leaders and key company profiles
  • Enterome
  • MicroBiome Therapeutics, LLC
  • Rebiotix Inc.
  • Yakult Honsha Co., Ltd.
  • Osel Inc.
  • Vedanta Biosciences, Inc.
  • Metabiomics Corporate
  • Synthetic Biologics, Inc.
  • DuPont
  • BiomX Ltd.
  • Get more information on this report

    Asia Pacific Human Microbiome Regional Insights

    The regional scope of Asia Pacific Human Microbiome refers to the geographical area in which a business operates and competes. Understanding regional nuances, such as local consumer preferences, economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved regions or adapting their offerings to meet regional demands. A clear regional focus allows for more effective resource allocation, targeted marketing, and better positioning against local competitors, ultimately driving growth in those specific areas.

    geography/asia-pacific-human-microbiome-market-geography.webp
    Get more information on this report

    The List of Companies - Asia Pacific Human Microbiome Market

    The List of Companies - Asia Pacific Human Microbiome Market

    1. Enterome
    2. MicroBiome Therapeutics, LLC
    3. Rebiotix Inc.
    4. Yakult Honsha Co., Ltd.
    5. Osel Inc.
    6. Vedanta Biosciences, Inc.
    7. Metabiomics Corporate
    8. Synthetic Biologics, Inc.
    9. DuPont
    10. BiomX Ltd.
    Frequently Asked Questions
    How big is the Asia Pacific Human Microbiome Market?

    The Asia Pacific Human Microbiome Market is valued at US$ 41.73 Million in 2017, it is projected to reach US$ 207.81 Million by 2025.

    What is the CAGR for Asia Pacific Human Microbiome Market by (2018 - 2025)?

    As per our report Asia Pacific Human Microbiome Market, the market size is valued at US$ 41.73 Million in 2017, projecting it to reach US$ 207.81 Million by 2025. This translates to a CAGR of approximately 22.8% during the forecast period.

    What segments are covered in this report?

    The Asia Pacific Human Microbiome Market report typically cover these key segments-

  • 产品 (益生菌, 食品, 益生元, 医疗食品, 诊断设备, 药物, 补充剂)
  • 疾病 (肥胖症, 糖尿病, 自身免疫性疾病, 癌症, 精神障碍)
  • 应用 (治疗学, 诊断学)
  • What is the historic period, base year, and forecast period taken for Asia Pacific Human Microbiome Market?

    The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Asia Pacific Human Microbiome Market report:

  • Historic Period : 2015-2016
  • Base Year : 2017
  • Forecast Period : 2018-2025
  • Who are the major players in Asia Pacific Human Microbiome Market?

    The Asia Pacific Human Microbiome Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:

  • Enterome
  • MicroBiome Therapeutics, LLC
  • Rebiotix Inc.
  • Yakult Honsha Co., Ltd.
  • Osel Inc.
  • Vedanta Biosciences, Inc.
  • Metabiomics Corporate
  • Synthetic Biologics, Inc.
  • DuPont
  • BiomX Ltd.
  • Who should buy this report?

    The Asia Pacific Human Microbiome Market report is valuable for diverse stakeholders, including:

    • Investors: Provides insights for investment decisions pertaining to market growth, companies, or industry insights. Helps assess market attractiveness and potential returns.
    • Industry Players: Offers competitive intelligence, market sizing, and trend analysis to inform strategic planning, product development, and sales strategies.
    • Suppliers and Manufacturers: Helps understand market demand for components, materials, and services related to concerned industry.
    • Researchers and Consultants: Provides data and analysis for academic research, consulting projects, and market studies.
    • Financial Institutions: Helps assess risks and opportunities associated with financing or investing in the concerned market.

    Essentially, anyone involved in or considering involvement in the Asia Pacific Human Microbiome Market value chain can benefit from the information contained in a comprehensive market report.